Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LY294002 suppresses the malignant phenotype and sensitizes osteosarcoma cells to pirarubicin chemotherapy.

Molecular medicine reports - 1 Dec 2014

Long Xin Hua, Zhong Zhen Hao, Peng Ai Fen, Zhu Liang Bo, Wang Heng, Zhang Guo Mei, Liu Zhi Li

Abstract excerpt

Pirarubicin is frequently used in chemotherapy against tumors. However, clinical use is severely limited by the development of progressive dose-dependent cardiomyopathy and acquired drug resistance. LY294002 is a commonly used pharmacologic inhibitor, which selectively inhibits the phosphoinositide 3-kinase-AKT nexus. The aim of this study was to investigate the combined inhibitory effect of LY294002 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Neoplasms
Share to Cell Movement

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromones

Share to Doxorubicin

Share to Morpholines

Share to Osteosarcoma

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Source

Identifiers

PMID: 25310590
DOI: 10.3892/mmr.2014.2617

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LY294002 suppresses the malignant phenotype and sensitizes osteosarcoma cells to pirarubicin chemotherapy.PMID 25310590Read ↗

LY294002 inhibits the malignant phenotype of osteosarcoma cells by modulating the phosphatidylinositol 3‑kinase/Akt/fatty acid synthase signaling pathway in vitro.Semantic proximity Read ↗

MicroRNA-340-5p inhibits the malignant phenotypes of osteosarcoma by directly targeting NRF2 and deactivating the PI3K/AKT pathway.Semantic proximity Read ↗

Silencing Livin gene expression by RNA interference enhanced the chemotherapeutic sensitivity of drug-resistant MG-63 osteosarcoma cells to doxorubicinSemantic proximity Read ↗

Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in OsteosarcomaSemantic proximity Read ↗

Robinetin Modulates TGF-β/ERK Signaling and Tumor-Associated Phenotype in 3D Osteosarcoma Spheroids.Semantic proximity Read ↗

Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcomaSemantic proximity Read ↗

FoxG1/BNIP3 axis promotes mitophagy and blunts cisplatin resistance in osteosarcomaSemantic proximity Read ↗

Huaier Extract Inhibits Proliferation and Promotes Apoptosis via the MAPK Pathway in Human Osteosarcoma CellsSemantic proximity Read ↗

Long non-coding RNA LINC00426 contributes to doxorubicin resistance by sponging miR-4319 in osteosarcomaSemantic proximity Read ↗

Paris polyphyllaSuppresses Proliferation and Vasculogenic Mimicry of Human Osteosarcoma Cells and Inhibits Tumor GrowthIn VivoSemantic proximity Read ↗

Drug Repurposing of β-blocker Propranolol in Osteosarcoma: Preclinical Antitumor Efficacy Alone or in Combination with Chemotherapy.Semantic proximity Read ↗

Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53‐dependent pathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.